TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
Brief Summary: The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF).

Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by chart review, who are matched to the prospective randomized subjects, will be identified. The purpose of the retrospective warfarin cohort is to compare the efficacy and safety of warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted, combined uninterrupted and interrupted).


Options:
A: Arm Label: Interrupted apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interrupted apixaban | Arm Label: Uninterrupted apixaban; Type: EXPERIMENTAL; Interventions: Drug: Uninterrupted apixaban | Intervention Type: DRUG; Name: Interrupted apixaban; Assigned to Arm(s): Interrupted apixaban | Intervention Type: DRUG; Name: Uninterrupted apixaban; Assigned to Arm(s): Uninterrupted apixaban
B: Arm Label: Bridging anti-coagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin or unfractionated heparin | Arm Label: Continued oral anti-coagulation; Type: EXPERIMENTAL; Interventions: Drug: Warfarin or coumadin | Intervention Type: DRUG; Name: low molecular weight heparin or unfractionated heparin; Assigned to Arm(s): Bridging anti-coagulation | Intervention Type: DRUG; Name: Warfarin or coumadin; Assigned to Arm(s): Continued oral anti-coagulation
C: Arm Label: Study Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coumadin | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coumadin | Intervention Type: DRUG; Name: Coumadin; Assigned to Arm(s): Study Arm | Intervention Type: DRUG; Name: Coumadin; Assigned to Arm(s): Control Arm | Intervention Type: DRUG; Name: Coumadin; Assigned to Arm(s): Control Arm, Study Arm
D: Arm Label: Standard medical therapy group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Catheter ablation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter ablation | Intervention Type: PROCEDURE; Name: Catheter ablation; Assigned to Arm(s): Catheter ablation group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs
Brief Summary: The purpose of this study is to determine whether varying the frequency and length of activity breaks during the workday will differentially impact sedentary behavior and health outcomes. Participants will be randomly assigned to take short, frequent breaks (i.e., 1 minute every half hour) or longer, planned breaks (i.e., two 15-minute walks) from sitting during the workday. They will be instructed to follow the assigned protocols for an 8-week intervention and the effects of their participation on sedentary behavior and a variety of health outcomes will be assessed. The investigators anticipate participants in both intervention arms will demonstrate significant reductions in daily sitting time, bit do not have an a priori hypothesis regarding the relative effectiveness of each approach.


Options:
A: Arm Label: Motivational lifestyle counselling; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Lifestyle Counselling | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Lifestyle Counselling; Assigned to Arm(s): Motivational lifestyle counselling
B: Arm Label: Short breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short breaks | Arm Label: Long breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long breaks | Intervention Type: BEHAVIORAL; Name: Short breaks; Assigned to Arm(s): Short breaks | Intervention Type: BEHAVIORAL; Name: Long breaks; Assigned to Arm(s): Long breaks
C: Arm Label: Physical Activity Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Intervention | Arm Label: Wellness Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness Control | Intervention Type: BEHAVIORAL; Name: Physical Activity Intervention; Assigned to Arm(s): Physical Activity Intervention | Intervention Type: BEHAVIORAL; Name: Wellness Control; Assigned to Arm(s): Wellness Control
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: text messages related to sedentary behaviour | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text messages related to sedentary behaviour; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs
Brief Summary: The purpose of this study is to determine whether varying the frequency and length of activity breaks during the workday will differentially impact sedentary behavior and health outcomes. Participants will be randomly assigned to take short, frequent breaks (i.e., 1 minute every half hour) or longer, planned breaks (i.e., two 15-minute walks) from sitting during the workday. They will be instructed to follow the assigned protocols for an 8-week intervention and the effects of their participation on sedentary behavior and a variety of health outcomes will be assessed. The investigators anticipate participants in both intervention arms will demonstrate significant reductions in daily sitting time, bit do not have an a priori hypothesis regarding the relative effectiveness of each approach.


Options:
A: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
B: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: A workplace "sit less and move more" web-based program for Spanish office employees | Arm Label: Active comparison group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparison group | Intervention Type: BEHAVIORAL; Name: A workplace "sit less and move more" web-based program for Spanish office employees; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Active Comparison group; Assigned to Arm(s): Active comparison group
D: Arm Label: Short breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short breaks | Arm Label: Long breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long breaks | Intervention Type: BEHAVIORAL; Name: Short breaks; Assigned to Arm(s): Short breaks | Intervention Type: BEHAVIORAL; Name: Long breaks; Assigned to Arm(s): Long breaks

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs
Brief Summary: The purpose of this study is to determine whether varying the frequency and length of activity breaks during the workday will differentially impact sedentary behavior and health outcomes. Participants will be randomly assigned to take short, frequent breaks (i.e., 1 minute every half hour) or longer, planned breaks (i.e., two 15-minute walks) from sitting during the workday. They will be instructed to follow the assigned protocols for an 8-week intervention and the effects of their participation on sedentary behavior and a variety of health outcomes will be assessed. The investigators anticipate participants in both intervention arms will demonstrate significant reductions in daily sitting time, bit do not have an a priori hypothesis regarding the relative effectiveness of each approach.


Options:
A: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group
B: Arm Label: Control condition; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Physical Activity Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity coaching | Intervention Type: BEHAVIORAL; Name: physical activity coaching; Assigned to Arm(s): Physical Activity Coaching
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention group | Arm Label: Intervention control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control group | Intervention Type: BEHAVIORAL; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: Control group; Assigned to Arm(s): Intervention control
D: Arm Label: Short breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short breaks | Arm Label: Long breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long breaks | Intervention Type: BEHAVIORAL; Name: Short breaks; Assigned to Arm(s): Short breaks | Intervention Type: BEHAVIORAL; Name: Long breaks; Assigned to Arm(s): Long breaks

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Parasite Elimination in the Human and Mosquito to Reduce Malaria Transmission: A Cluster Randomised Controlled Factorial Design Trial of Reactive Focal Drug Administration (rfMDA) Versus Reactive Case Detection (RACD), With and Without Reactive Vector Control (RAVC), From the Low Endemic Setting of Namibia
Brief Summary: This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus reactive case detection (RACD), and 2) reactive IRS (indoor residual spraying) versus control on the incidence of malaria in Namibia.


Options:
A: Arm Label: Conventional Olyset LLIN; Type: EXPERIMENTAL; Interventions: Other: Conventional Olyset LLIN | Arm Label: Olyset Plus LLIN; Type: EXPERIMENTAL; Interventions: Other: Olyset Plus LLIN | Arm Label: Conventional Olyset LLIN and IRS; Type: EXPERIMENTAL; Interventions: Other: Conventional Olyset LLIN, Other: IRS | Arm Label: Olyset Plus LLIN and IRS; Type: EXPERIMENTAL; Interventions: Other: Olyset Plus LLIN, Other: Conventional Olyset LLIN | Intervention Type: OTHER; Name: Olyset Plus LLIN; Assigned to Arm(s): Olyset Plus LLIN, Olyset Plus LLIN and IRS | Intervention Type: OTHER; Name: Conventional Olyset LLIN; Assigned to Arm(s): Conventional Olyset LLIN, Conventional Olyset LLIN and IRS, Olyset Plus LLIN and IRS | Intervention Type: OTHER; Name: IRS; Assigned to Arm(s): Conventional Olyset LLIN and IRS
B: Arm Label: Participants; Type: OTHER; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): Participants
C: Arm Label: RACD without RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: RACD | Arm Label: RACD+RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: RACD, Combination Product: RAVC | Arm Label: rfMDA without RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: RAVC, Combination Product: rfMDA | Arm Label: rfMDA+RAVC; Type: EXPERIMENTAL; Interventions: Combination Product: rfMDA | Intervention Type: COMBINATION_PRODUCT; Name: RACD; Assigned to Arm(s): RACD without RAVC, RACD+RAVC | Intervention Type: COMBINATION_PRODUCT; Name: RAVC; Assigned to Arm(s): RACD+RAVC, rfMDA without RAVC | Intervention Type: COMBINATION_PRODUCT; Name: rfMDA; Assigned to Arm(s): rfMDA without RAVC, rfMDA+RAVC
D: Arm Label: IRS; Type: EXPERIMENTAL; Interventions: Other: Actellic CS | Arm Label: non-IRS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Actellic CS; Assigned to Arm(s): IRS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial
Brief Summary: This study examines patients on chronic hemodialysis with non-valvular atrial fibrillation, who have a CHA2DS2-VASc Score of ≥ 2 and therefore are candidates for or already receive a vitamin K antagonist.

The first question is whether replacement of the vitamin K antagonist by rivaroxaban is able to slow progression of vascular calcification. The second question is whether addition of vitamin K2 to rivaroxaban can further slow down or even halt the progression of vascular calcification.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: law molecular weigth heparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: unfractioned heparin | Intervention Type: DRUG; Name: law molecular weigth heparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: unfractioned heparin; Assigned to Arm(s): B
B: Arm Label: nafamostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat Mesylate | Arm Label: Cnoxane; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Nafamostat Mesylate; Assigned to Arm(s): nafamostat
C: Arm Label: Vitamin K antagonist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: rivaroxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban | Arm Label: rivaroxaban and vitamin K2; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban, Dietary Supplement: Vitamin K2 | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): rivaroxaban, rivaroxaban and vitamin K2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin K2; Assigned to Arm(s): rivaroxaban and vitamin K2
D: Arm Label: Placebo without anticoagulation; Type: PLACEBO_COMPARATOR; Interventions: Drug: catheter induced thromboprophylaxis | Arm Label: Low Dose Direct Oral Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: catheter induced thromboprophylaxis | Intervention Type: DRUG; Name: catheter induced thromboprophylaxis; Assigned to Arm(s): Low Dose Direct Oral Anticoagulation, Placebo without anticoagulation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Technology Apps Improve Compliance in Adolescent Renal Transplant Recipients?
Brief Summary: The purpose of this study is to empower adolescent renal transplant recipients to fully understand their medical condition as well as to help them acquire the skills to maintain a healthy allograft well into adulthood. It is hoped that introducing technological applications (apps) will assist adolescents in managing medications, clinic appointments, lab appointments, and in tracking fluid intake, blood pressure, caloric intake, and exercise frequency. The investigators aim to improve adolescent post-renal transplant outcomes (increase medication adherence, lower clinic and laboratory no-show rate, lower blood pressure and BMI, maintain creatinine clearance, decrease proteinuria, decrease incidence of allograft rejection, decrease hospitalizations) as well as reduce cost.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program with monthly sessions | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Usual Care, containing one session | Intervention Type: BEHAVIORAL; Name: Self-management program with monthly sessions; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Usual Care, containing one session; Assigned to Arm(s): Control
B: Arm Label: SMASK; Type: EXPERIMENTAL; Interventions: Behavioral: SMASK | Arm Label: EnhancedSC; Type: OTHER; Interventions: Behavioral: EnhancedSC | Intervention Type: BEHAVIORAL; Name: SMASK; Assigned to Arm(s): SMASK | Intervention Type: BEHAVIORAL; Name: EnhancedSC; Assigned to Arm(s): EnhancedSC
C: Arm Label: SystemCHANGE; Type: EXPERIMENTAL; Interventions: Behavioral: SystemCHANGE | Arm Label: Patient-education attention-control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient-education attention control | Intervention Type: BEHAVIORAL; Name: SystemCHANGE; Assigned to Arm(s): SystemCHANGE | Intervention Type: BEHAVIORAL; Name: Patient-education attention control; Assigned to Arm(s): Patient-education attention-control
D: Arm Label: Paper-based; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Paper-based | Arm Label: Electronic application; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic application | Intervention Type: BEHAVIORAL; Name: Electronic application; Assigned to Arm(s): Electronic application | Intervention Type: BEHAVIORAL; Name: Paper-based; Assigned to Arm(s): Paper-based

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Video Laryngoscopy (Video Macintosh-blade) and Direct Laryngoscopy (EMMA-Study): A Prospective, Randomized Trial
Brief Summary: A randomized controlled prospective study of laryngoscopy and intubation success comparing direct laryngoscopy and the McGrath® Mac videolaryngoscope.


Options:
A: Arm Label: Videolaryngoscope McGrath Mac; Type: ACTIVE_COMPARATOR; Interventions: Device: Videolaryngoscope | Arm Label: Standard laryngoscope; Type: PLACEBO_COMPARATOR; Interventions: Device: Standard laryngoscope | Intervention Type: DEVICE; Name: Videolaryngoscope; Assigned to Arm(s): Videolaryngoscope McGrath Mac | Intervention Type: DEVICE; Name: Standard laryngoscope; Assigned to Arm(s): Standard laryngoscope
B: Arm Label: McGrath MAC; Type: EXPERIMENTAL; Interventions: Device: the McGrath MAC | Arm Label: Macintosh Laryngoscope; Type: EXPERIMENTAL; Interventions: Device: the Macintosh Laryngoscope | Intervention Type: DEVICE; Name: the McGrath MAC; Assigned to Arm(s): McGrath MAC | Intervention Type: DEVICE; Name: the Macintosh Laryngoscope; Assigned to Arm(s): Macintosh Laryngoscope
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Macintosh blade, Device: D-Blade, Device: Intubation | Intervention Type: DEVICE; Name: Macintosh blade; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: D-Blade; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: Intubation; Assigned to Arm(s): Intervention
D: Arm Label: GlideScope (GVL) Blade; Type: ACTIVE_COMPARATOR; Interventions: Device: Laryngoscopy with GlideScope (GVL) Blade | Arm Label: MacIntosh (MAC) Blade; Type: ACTIVE_COMPARATOR; Interventions: Device: Laryngoscopy with MacIntosh (MAC) Blade | Intervention Type: DEVICE; Name: Laryngoscopy with GlideScope (GVL) Blade; Assigned to Arm(s): GlideScope (GVL) Blade | Intervention Type: DEVICE; Name: Laryngoscopy with MacIntosh (MAC) Blade; Assigned to Arm(s): MacIntosh (MAC) Blade

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FIRST-ABC Feasibility Study: Feasibility Study for a Randomised Trial of High Flow Nasal Cannula (HFNC) Versus Continuous Positive Airway Pressure (CPAP) for Non-invasive Respiratory Support in Critically Ill Children
Brief Summary: A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill children


Options:
A: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A
B: Arm Label: high flow nasal cannula (HFNC); Type: ACTIVE_COMPARATOR; Interventions: Device: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices | Arm Label: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV); Type: ACTIVE_COMPARATOR; Interventions: Device: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices | Intervention Type: DEVICE; Name: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices; Assigned to Arm(s): high flow nasal cannula (HFNC), nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)
C: Arm Label: High flow nasal cannula (HFNC); Type: EXPERIMENTAL; Interventions: Device: Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula | Arm Label: Continuous positive airway pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure | Intervention Type: DEVICE; Name: Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula; Assigned to Arm(s): High flow nasal cannula (HFNC) | Intervention Type: DEVICE; Name: Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure; Assigned to Arm(s): Continuous positive airway pressure (CPAP)
D: Arm Label: HSS (3%) + epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epinephrine 1/1000, Drug: HSS 3% | Arm Label: HHHFNC+epinephrine+Normal Saline(0.9%); Type: EXPERIMENTAL; Interventions: Drug: Epinephrine 1/1000, Device: HHHFNC, Drug: NS (0.9%) | Intervention Type: DRUG; Name: Epinephrine 1/1000; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%), HSS (3%) + epinephrine | Intervention Type: DRUG; Name: HSS 3%; Assigned to Arm(s): HSS (3%) + epinephrine | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%) | Intervention Type: DRUG; Name: NS (0.9%); Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%)

Answer: C